Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life-threatening diseases. The company is headquartered in Hayward, California and currently employs 21 full-time employees. The company went IPO on 2010-03-02. The firm has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.
Follow-Up Questions
Anthera Pharmaceuticals Inc 'in CEO'su kimdir?
Mr. J. Craig Thompson 2016 'den beri şirketle birlikte olan Anthera Pharmaceuticals Inc 'in President 'ıdır.
ANTH hissesinin fiyat performansı nasıl?
ANTH 'in mevcut fiyatı $0.0001 'dir, son işlem günde 0% decreased etti.
Anthera Pharmaceuticals Inc için ana iş temaları veya sektörler nelerdir?
Anthera Pharmaceuticals Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
